We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Elevated Vitamin-B12 Level Lowers Risk of Parkinson’s Disease Dementia

By LabMedica International staff writers
Posted on 15 Apr 2020
Previous studies found that, among people with Parkinson’s, those with cognitive impairment, such as dementia, had significantly lower levels of vitamin B12 in their blood. More...
This suggests the possibility that low vitamin B12 or cobalamin levels predispose certain individuals to dementia.

Dementia describes a group of symptoms in which memory and cognitive abilities become impaired enough to affect daily life. Dementia can be part of the non-motor symptoms associated with Parkinson’s disease (PD); it is most common among people who are older and/or have had Parkinson’s symptoms for longer.

A group of scientists working with the Mayo Clinic College of Medicine and Science (Rochester, MN, USA) utilized a population-based cohort of Parkinsonism patients to examine the relationship between serum vitamin B12 at the time of PD diagnosis and dementia risk. Receiver operating curves were calculated for vitamin B12 cutoffs maximizing sensitivity and specificity for determining who developed dementia. Time from Parkinsonism diagnosis to dementia, death, or censoring was calculated. There were 25 people with Parkinson’s (17 males, eight females) whose data also included a measurement of blood B12 levels within either one year before or three months after their diagnosis.

The team reported that the median age of the group at diagnosis was 74 years. Of the 25 people included, 15 (60%) were later diagnosed with dementia, at a median age of 79.4 years. On average, individuals who did not develop dementia had significantly higher vitamin B12 levels when they were diagnosed than those who did, 648.5 versus 452 ng/L. With additional statistical modeling, they found that a cutoff of 587 ng/L could separate those who did or did not develop dementia, with an overall sensitivity (true-positive rate) of 87% and a specificity (true-negative rate) of 70%. They further calculated that for every 100 ng/L increase in vitamin B12 levels at diagnosis, there was a statistically significant decrease in dementia risk; such that a vitamin B12 level of 500 ng/L was associated with a 69% reduced risk of dementia compared with 400 ng/L.

The authors concluded that the association between higher serum B12 levels and decreased dementia risk may provide prognostic information for clinicians as they counsel patients on the disease course of PD and raises further questions regarding the potential importance of vitamin B12 in these patients. The study was published on March 16, 2020 in the journal Parkinsonism & Related Disorders.

Related Links:
Mayo Clinic College of Medicine and Science


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.